NICE recommends Zydelig (idelalisib) for the treatment of chronic lymphocytic leukaemia

Gilead Sciences’ Zydelig® (idelalisib) has been recommended by the National Institute for Health and Care Excellence (NICE) as a treatment option in combination with rituximab for adults with… Source link